Claudia D Baldus
Overview
Explore the profile of Claudia D Baldus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, et al.
Haematologica
. 2024 Apr;
109(8):2469-2477.
PMID: 38654660
In newly diagnosed acute myeloid leukemia (AML), immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pretherapeutic risk factors....
12.
Rollig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich B, Hanoun M, et al.
Br J Haematol
. 2024 Apr;
204(6):2254-2258.
PMID: 38593353
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy...
13.
Kroeze E, Iaccarino I, Kleisman M, Mondal M, Beder T, Khouja M, et al.
Blood
. 2024 Apr;
144(1):74-83.
PMID: 38588489
Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in the bone marrow or blood (BCP acute lymphoblastic leukemia [BCP-ALL]) or are less common in extramedullary tissue (BCP...
14.
Burmeister T, Stroh A, Kehden B, Trautmann H, Meyer C, Marschalek R, et al.
Leukemia
. 2024 Mar;
38(7):1600-1603.
PMID: 38519799
No abstract available.
15.
Eckardt J, Hahn W, Rollig C, Stasik S, Platzbecker U, Muller-Tidow C, et al.
NPJ Digit Med
. 2024 Mar;
7(1):76.
PMID: 38509224
Clinical research relies on high-quality patient data, however, obtaining big data sets is costly and access to existing data is often hindered by privacy and regulatory concerns. Synthetic data generation...
16.
Georgi J, Stasik S, Kramer M, Meggendorfer M, Rollig C, Haferlach T, et al.
Leukemia
. 2024 Jan;
38(2):281-290.
PMID: 38228680
Despite recent refinements in the diagnostic and prognostic assessment of CEBPA mutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations,...
17.
Bastian L, Beder T, Barz M, Bendig S, Bartsch L, Walter W, et al.
Blood
. 2023 Dec;
143(14):1391-1398.
PMID: 38153913
Distinct diagnostic entities within BCR::ABL1-positive acute lymphoblastic leukemia (ALL) are currently defined by the International Consensus Classification of myeloid neoplasms and acute leukemias (ICC): "lymphoid only", with BCR::ABL1 observed exclusively...
18.
Eckardt J, Stasik S, Rollig C, Petzold A, Sauer T, Scholl S, et al.
Leukemia
. 2023 Oct;
37(12):2395-2403.
PMID: 37833543
Genetic lesions of IKZF1 are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute...
19.
Eckardt J, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, et al.
Leukemia
. 2023 Sep;
37(11):2282-2285.
PMID: 37679502
No abstract available.
20.
Kelm M, Darzentas F, Darzentas N, Kotrova M, Wessels W, Bendig S, et al.
Hemasphere
. 2023 Sep;
7(9):e948.
PMID: 37670805
No abstract available.